Aurora Spine (ASG) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue grew 0.4% year-over-year to $4.44 million, with strong March sales and direct sales initiatives offsetting a slow start due to weather and market pressures.

• Proprietary products, especially the DEXA platform, SiLO franchise, and Zip implants, drove growth, supported by new product launches and patent issuances that strengthened the IP portfolio.

• Biologics sales surged 124% year-over-year following the late 2025 launch, contributing $0.2 million in Q1 2026.

• Sales team expansion and optimization are underway, with five new hires and a focus on underpenetrated regions to support future growth.

• EBITDAC improved by $127,689 year-over-year, reaching $107,000 in Q1 2026, a turnaround from a negative $20,000 a year ago.

Financial highlights

• Gross margin improved to 62.6%, up 460 basis points from 58% in Q1 2025, driven by higher direct sales of proprietary products.

• Operating expenses were $2.98 million, up slightly from $2.88 million in Q1 2025, reflecting tight expense controls and higher compensation.

• Net loss narrowed to $203,000 from $350,000 in Q1 2025; EPS remained at $0.0 per share.

• Cash position at March 31, 2026 was $778,006, down from $896,713 at December 31, 2025.

Outlook and guidance

• Q2 2026 revenue is expected to be in line or slightly lower than the prior year, reflecting ongoing sales team reorganization.

• Growth is anticipated in the second half of 2026, driven by new product launches, expanded sales coverage, and DEXA-L availability for lumbar applications.

• Management targets 15-20% year-over-year sales growth through regional expansion and new product adoption.